TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00086671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-874/Human monoclonal antibody against IL-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-874/Human monoclonal antibody against IL-12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03608826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational LINQ™ HF RAMware
Description: The Reveal LINQ™ device and the 2090 programmer are market-released, but once the investigational LINQ™ HF RAMware is downloaded into the devices, they are considered investigational.
Study: NCT00183079

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivationally-focused brief alcohol intervention
Description: Brief, motivationally-focused alcohol intervention
Study: NCT04454424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Study intervention BAY1817080 will be administered orally with tablet(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Study intervention BAY1817080 will be administered orally with tablet(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Study intervention BAY1817080 will be administered orally with tablet(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Study intervention BAY1817080 will be administered orally with tablet(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Study intervention BAY1817080 will be administered orally with tablet(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered intravenously with dose of 0.1 mg on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered intravenously with dose of 0.1 mg on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered intravenously with dose of 0.1 mg on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered intravenously with dose of 0.1 mg on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered intravenously with dose of 0.1 mg on Day 1.
Study: NCT03122795

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microbiome transplant
Description: A raw microbiome, collected from a donor without any sinonasal health problems, as a nasal lavage.
Study: NCT01725672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin, 500 mg extended release tablet
Description: In Part A and Part B of the study, Metformin 500 mg XR tablet will be administered with 240 millilitre (mL) water ; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin, 1000 mg extended release tablet
Description: In Part A and Part B of the study, Metformin 1000 mg XR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride, 1 mg immediate release tablet
Description: In Part A and Part B of the study, Glimepiride 1 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride, 2 mg immediate release tablet
Description: In Part A and Part B of the study, Glimepiride 2 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers
Description: In Part A of the study, 1 XR film coated tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers
Description: In Part A of the study, 1 XR film coated tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers
Description: In Part B of the study, 1 XR tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers
Description: In Part B of the study, 1 XR tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
Study: NCT03927170

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Janumet XR tablet 100/1000 mg
Description: To administrate the Janumet XR tablet

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GLH1SM tablet 100/1000 mg
Description: To administrate the GLH1SM tablet
Study: NCT04031716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Participants assigned to the Meditation intervention will receive focused attention meditation training preoperatively, and encouraged to meditate for 20 minutes per day before surgery. In the postoperative inpatient period, the participants will be offered standard holistic health care, reinforcement of meditation training, and encouragement to practice at least 20 minutes of guided focused-attention meditation with breath as their focus, utilizing the MUSETM headband for bio-feedback, every day during their hospital stay. They will be asked to continue using the MUSETM neurofeedback-assisted meditation after hospital discharge, until their visit to repeat pain testing, at which time they will return the MUSETM headband.
Study: NCT01705041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostics for All liver function test (LFT)
Description: HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
Study: NCT00848497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testim®
Description: Testim® 5 g of gel (one tube) containing 50 mg of testosterone once daily. This was the dose given to the patient which he started.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Testim®
Description: Placebo Testim® 5 g of gel (one tube)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Viagra®
Description: Viagra 25mg was the dose given to the patient which he started.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viagra®
Description: Viagra 25mg was the dose given to the patient which he started.
Study: NCT01104961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens packaging solution
Description: These test solutions are the intervention being tested.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens packaging solution
Description: These test solutions are the intervention being tested.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Balanced salt solution (BSS)
Description: BSS is isotonic to the tissues of the eyes.
Study: NCT00469131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus + steroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus + mycophenolate mofetil
Study: NCT00671268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AL0704rP
Description: strict subcutaneous

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: strict subcutaneous
Study: NCT00349336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5mg/kg iv on day 1 of each 2 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX-4
Description: As prescribed
Study: NCT03951519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral administration of water
Description: Volume expansion via 500 mL of water administered by the patient's nasogastric tube

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: administration of saline solution
Description: Volume expansion via 500 mL of saline (Nacl 0.9%) administered by the venous route
Study: NCT01256515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: CDs, techniques, advice, and group training pertaining to a healthier lifestyle. Both groups will have this intervention, but the specific type of health education training will vary between groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: CDs, techniques, advice, and group training pertaining to a healthier lifestyle. Both groups will have this intervention, but the specific type of health education training will vary between groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education Training
Description: 8 weeks of group training regarding health education techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Training
Description: 8 weeks of group training regarding health education techniques.
Study: NCT04538508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diathermy
Description: 10 sessions of 12 minutes of radiofrequency diathermy at the anterior surface of the knee, in constant movement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised knee exercises
Description: Daily hamstrings exercises, quadriceps exercises and hip exercises, 20 minutes of duration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised knee exercises
Description: Daily hamstrings exercises, quadriceps exercises and hip exercises, 20 minutes of duration.
Study: NCT02966834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GSK2330672 matching placebo will be supplied as white film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GSK2330672 matching placebo will be supplied as white film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GSK2330672 matching placebo will be supplied as white film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GSK2330672 matching placebo will be supplied as white film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GSK2330672 matching placebo will be supplied as white film-coated tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: GSK2330672 matching placebo will be supplied as white film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672
Description: GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672
Description: GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672
Description: GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672
Description: GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672
Description: GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.
Study: NCT02351921

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Intermittent theta-burst stimulation is a form of repetitive Transcranial magnetic stimulation. ITBS is a non-invasive, non-painful procedure being used worldwide to study brain function and promote short-term changes (\~1 hour) in neural activity in the brain. The delivery of cTBS requires \~ 40 seconds in total.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Intermittent theta-burst stimulation is a form of repetitive Transcranial magnetic stimulation. ITBS is a non-invasive, non-painful procedure being used worldwide to study brain function and promote short-term changes (\~1 hour) in neural activity in the brain. The delivery of cTBS requires \~ 40 seconds in total.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Intermittent theta-burst stimulation is a form of repetitive Transcranial magnetic stimulation. ITBS is a non-invasive, non-painful procedure being used worldwide to study brain function and promote short-term changes (\~1 hour) in neural activity in the brain. The delivery of cTBS requires \~ 40 seconds in total.
Study: NCT03380286

Intervention type: DEVICE
Intervention: Firehawk
Description: Firehawk stent
Study: NCT00544414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03783637

Intervention type: OTHER
Group type: OTHER
Intervention: Whole grain oats
Description: A meal containing whole grain oats

Intervention type: OTHER
Group type: OTHER
Intervention: Whole grain wheat
Description: A meal containing whole grain wheat
Study: NCT00720499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL plus tiotropium bromide
Description: BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL plus tiotropium bromide
Description: BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
Study: NCT03888053

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BB-101
Description: Within each cohort, 8 subjects will be randomized to receive BB-101 and 4 subjects to receive placebo.
Study: NCT04196127

Intervention type: OTHER
Intervention: Bite force testing
Description: Maximum bite force examination with a force intra-oral measuring device

Intervention type: OTHER
Intervention: Bite force testing
Description: Maximum bite force examination with a force intra-oral measuring device
Study: NCT00720499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat® Inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat® Inhaler
Study: NCT02825823

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Salt

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00611052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Adolescent Coping with Stress
Description: A group cognitive intervention, manualized and highly structured. Includes 8 sessions (á 1.5 hours) and a booster session 6 months after termination of the actual intervention. Groups leaders are specifically trained for this course.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The usual treatment received by the adolescent with mild to moderate self-reported depressive symptoms in school health care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual health education
Description: usual health education given by the school nurses, targeted for healthy controls with no depressive symptoms according to the self-report scale
Study: NCT01430377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SB predilatation
Description: Initial SB \[predilatation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No SB predilatation
Description: Without SB predilatation
Study: NCT03432260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928 30 mg
Description: Lowest dose of 3 dose escalation arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928 30 mg
Description: Lowest dose of 3 dose escalation arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928 90 mg
Description: Middle dose of 3 dose escalation arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928 90 mg
Description: Middle dose of 3 dose escalation arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928 150 mg
Description: Highest dose of 3 dose escalation arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928 150 mg
Description: Highest dose of 3 dose escalation arms.
Study: NCT00914368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients not already on clopidogrel treatment a loading dose of clopidogrel 600 mg followed by a maintenance dose of 75 mg once daily will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients not already on clopidogrel treatment a loading dose of clopidogrel 600 mg followed by a maintenance dose of 75 mg once daily will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients not already on clopidogrel treatment a loading dose of clopidogrel 600 mg followed by a maintenance dose of 75 mg once daily will be administered.
Study: NCT00427310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium heparin
Study: NCT03543800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytorich PRP kit
Description: Subjects randomized to the PRP treatment arm will receive PRP only without the anti-inflammatory component of ABP added

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PRP kit
Description: PRP kit legally marketed in Canada for PRP
Study: NCT02852070

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bronchoalveolar lavage 120ml
Description: 120mL sterile saline solution instilled into the distal bronchial tree in 3 times

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchoalveolar lavage 60ml
Description: 60mL sterile saline solution instilled into the distal bronchial tree in 3 times
Study: NCT04150315

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteome analysis
Description: Evaluation of specific protein levels in tissue and plasma.

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteome analysis
Description: Evaluation of specific protein levels in tissue and plasma.
Study: NCT03335046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Visit
Description: The intervention will consist of a series of home visitations to chronically absent students with co-morbid asthma. These visits will consist of a home environment evaluation, medication adherence and knowledge assessment, distribution of home environmental allergen reduction items such as mattress and pillow encasements, as well as review and reinforcement of any asthma action plans or care plans provided by patient's primary care physicians or medical home.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Home Visit
Description: The intervention will consist of a series of home visitations to chronically absent students with co-morbid asthma. These visits will consist of a home environment evaluation, medication adherence and knowledge assessment, distribution of home environmental allergen reduction items such as mattress and pillow encasements, as well as review and reinforcement of any asthma action plans or care plans provided by patient's primary care physicians or medical home.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Standard care will refer to the procedures carried out by the school district to address students with chronic absenteeism. This includes parent-teacher and parent-school administrator meetings and communications and may also include home visits carried out by classroom teachers or student support center staff.
Study: NCT03531749

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HIV+ MRPJ
Description: supplemented with (1g/d) MRPJ

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HIV+ MRPJ
Description: supplemented with (1g/d) MRPJ

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HIV+ ascorbic acid
Description: Supplemented with (1g/d) AA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HIV+ ascorbic acid
Description: Supplemented with (1g/d) AA
Study: NCT04872283

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: great toe (1st metatarsophalangeal joint) fusion
Description: Great Toe joint fusion surgery